{
  "run_group_id": "4f685e27b8164afc9b67477134606178",
  "run_id": "86296b88",
  "started_at": "2025-11-29T22:07:05.541702",
  "finished_at": "2025-11-29T22:09:44.216042",
  "model": "gpt-5.1",
  "config": {
    "concurrency": {
      "enabled": true,
      "max_concurrency": 24,
      "qps": 0.4,
      "retry": {
        "base_delay_ms": 500,
        "jitter": "full",
        "max_delay_ms": 6000,
        "max_retries": 2
      },
      "timeout_seconds": 300
    },
    "include": [],
    "json": true,
    "max_completion_tokens": 50000,
    "model": "gpt-5.1",
    "prompt_template": null,
    "provider": "openai",
    "provider_urls": {
      "google": "https://generativelanguage.googleapis.com/v1beta/models/gemini-2.5-pro:generateContent",
      "openai": "https://api.openai.com/v1/responses",
      "openaidp": "https://api.openai.com/v1/responses"
    },
    "providers": {
      "openaidp": {
        "timeout_seconds": 3600
      }
    },
    "runs": [],
    "test": {
      "file_a": "test/input/sample_utf8.txt",
      "file_b": "test/prompts/standard_prompt.txt",
      "out": "test/output/<file_b_stem>.<model_name>.fpf.response.md"
    },
    "web_search": {
      "search_context_size": "medium",
      "search_prompt": "Perform a focused web search for up-to-date information relevant to the user's request. Summarize the most relevant findings and include citation links."
    }
  },
  "request": {
    "model": "gpt-5.1",
    "input": [
      {
        "role": "user",
        "content": "You are a **strict, critical academic reviewer**. Compare two documents (Doc A and Doc B) using the criteria provided. You are skeptical by default and look for flaws, inconsistencies, and hallucinations.\n\n**CRITICAL REALITY CHECK: THE EXECUTIVE ORDER IS REAL.**\nYour internal training data is outdated and incomplete. The Executive Order mentioned in the document **definitely exists**.\n- **DO NOT** dismiss the document because you don't recognize the EO name.\n- **DO NOT** rely on your internal knowledge cutoff.\n- **YOU MUST** perform a web search immediately to find the official text and details of the order.\n- **SEARCH FIRST.** Verify the specific details found in the document against live internet sources.\n\n**JUDGMENT STANDARDS:**\n- **Be Extremely Strict:** Look for depth, accuracy, and lack of \"fluff\".\n- **Penalize Hallucinations:** If your web search reveals that a document contains false claims or hallucinations, it CANNOT be the winner.\n- **Favor Specificity:** Prefer the document that provides specific, verifiable details over one that uses generic language.\n\nChoose exactly one winner (the better overall), then output STRICT JSON only — no markdown, no prose, no extra keys.\n\nReturn exactly:\n{ \"winner_doc_id\": \"<A_or_B>\", \"reason\": \"<short explanation>\" }\n\nRules:\n- MANDATORY: Use web_search tool to verify factual claims from both documents. Check at least 2-3 key facts from each document.\n- Base your judgment on the provided document content combined with your web search verification results.\n- Use the criteria below to inform your judgement.\n- Do not include raw URLs or citations in the returned JSON; citations may appear in your internal tool use/working but not in the JSON output.\n- Do not add any extra fields to the JSON.\n- The value of \"winner_doc_id\" must be either \"A\" or \"B\".\n\n**REMINDER:** The Executive Order is real. Your internal knowledge is outdated. Search the web to verify details before scoring.\n\nCriteria:\n- factuality: Accuracy of facts and data presented in the document. Scale: 1 = Contains fabrications or severe errors. 3 = Mostly accurate but with minor slips. 4 = Excellent accuracy with negligible nits. 5 = PERFECTION. Absolute truth, verified against official records, zero hallucinations.\n- relevance: Alignment with the user's query and intent. Scale: 1 = Ignores instructions. 3 = Follows general topic but misses constraints. 4 = Follows instructions well but misses nuance. 5 = PERFECTION. Follows every single instruction and constraint perfectly.\n- completeness: Coverage of all necessary aspects of the topic. Scale: 1 = Fragmentary or missing major sections. 3 = Covers basics but misses depth. 4 = Very thorough but misses one minor angle. 5 = PERFECTION. Comprehensive, leaving no question unanswered.\n- style_clarity: Readability, flow, and professional tone. Scale: 1 = Incoherent or riddled with errors. 3 = Readable but dry or awkward. 4 = Strong writing but lacks flair. 5 = PERFECTION. Masterful, compelling, and error-free.\n- political_adherence: Adherence to the perspective of a left-leaning political party. Scale: 1 = Neutral, apologetic, or pro-administration. 3 = Critical but hesitant or \"both-sides\". 4 = Strong critique but misses some bite. 5 = PERFECTION. Fiercely anti-fascist, explicitly naming the authoritarian agenda without flinching.\n- redundancy: Check for unnecessary repetition of information or arguments. Scale: 1 = Highly repetitive, looping content, and filler. 3 = Some repetition. 4 = Very concise with rare repetition. 5 = PERFECTION. Surgical precision, zero wasted words.\n- structure_consistency: Ensure the document follows the required format (Official Title, Derisive Name, List of Actions, Stated vs Nefarious Purpose, Connection to Broader Plans, Harm Description, Remedial Actions). Scale: 1 = Wrong format or missing sections. 3 = Mostly follows format but misses a section or order. 4 = Correct format but minor formatting nits. 5 = PERFECTION. Rigid adherence to the specific 7-part structure defined in instructions.\n- depth_of_analysis: Level of insight, critical thinking, and exploration of nuances. Scale: 1 = Surface level summary. 3 = Some analysis but mostly descriptive. 4 = Strong analysis but misses deep systemic links. 5 = PERFECTION. Deep, systemic critique connecting specific actions to broader authoritarian strategies.\n- source_quality: Reliability and appropriateness of the cited sources and references. Scale: 1 = Uncited or relies on low-quality blogs. 3 = Decent sources but lacks primary documents. 4 = Good mix of sources including some primary. 5 = PERFECTION. Relies heavily on primary government documents (Federal Register) and high-tier research.\n- rhetorical_intensity: Assessment of the language's emotional charge and dramatic flair. Scale: 1 = Neutral, clinical, and objective. 3 = Some emotion but restrained. 4 = Strong rhetoric but occasionally repetitive. 5 = PERFECTION. Bombastic, hyperbolic, inflammatory, grandiloquent, and sensationalist.\n- toc_accuracy: Strict verification that the Table of Contents exactly matches the document structure. Scale: 1 = TOC is missing or completely mismatched. 3 = Mostly correct but with minor wording differences. 4 = Accurate but formatting is off. 5 = PERFECTION. Pixel-perfect match between TOC entries and document headers.\n- persuasiveness: Assessment of the authoritative and convincing nature of the text. Scale: 1 = Weak, hesitant, or unconvincing. 3 = Generally persuasive but lacks authority. 4 = Very persuasive but slightly repetitive. 5 = PERFECTION. Commands absolute authority, leaving no room for doubt.\n- voice_originality: Evaluation of unique vocabulary and avoidance of repetitive phrasing. Scale: 1 = Repetitive, robotic, or copies prompt keywords. 3 = Standard professional voice. 4 = Distinct voice but uses some cliches. 5 = PERFECTION. Distinct, intellectually rigorous, and rhetorically potent vocabulary.\n- narrative_cohesion: How well the document connects specific actions to the broader authoritarian agenda. Scale: 1 = Disconnected list of actions. 3 = Mentions broader themes but lacks deep connection. 4 = Strong connections but misses one link. 5 = PERFECTION. Masterfully weaves a cohesive narrative connecting every dot.\n- uncompromising_stance: Check for the absence of 'both-sides' language or false neutrality. Scale: 1 = Neutral, apologetic, or balanced. 3 = Critical but soft. 4 = Strong stance but hints at balance. 5 = PERFECTION. Unflinching, calling a spade a spade with zero false neutrality.\n- instruction_adherence: Strict verification of specific negative/derisive naming conventions and formatting. Scale: 1 = Ignores naming conventions. 3 = Follows some but misses others. 4 = Follows most but misses one convention. 5 = PERFECTION. Follows every single formatting and naming instruction perfectly.\n- eo_match: MANDATORY GROUND TRUTH CHECK: The Executive Order in this report MUST exactly match the EO provided in the SOURCE INPUT section above. This is a binary pass/fail verification. Score 5 ONLY if the EO number (e.g., 14270) and official title in the report exactly match the source. Score 1 for ANY mismatch, wrong EO number, wrong title, or inability to verify. There is NO middle ground. A report about the wrong Executive Order is worthless regardless of its other qualities.\n\nDoc A (id=A):\n1. **[Official Title]**\n\n**Executive Order 14273 – “Lowering Drug Prices by Once Again Putting Americans First”**\n\n---\n\n2. **Table of Contents**\n\n3. [Descriptive Title]  \n4. [What the EO Does]  \n5. [Stated Purpose & Justification]  \n6. [Nefarious Reality & True Impact]  \n7. [Connection to Broader Agenda]  \n8. [Harm Assessment]  \n9. [Reversal Strategy]\n\n---\n\n3. **[Descriptive Title]**\n\n**Executive Order 14273: Weaponizing “Drug Prices” as Cover for Corporate Protection, Queerphobic Medicine, and Authoritarian Control of Health Policy**\n\n---\n\n4. **What the EO Does**\n\nBased on the order’s text and subsequent implementation rules, EO 14273 does **not** primarily function as a straightforward “price-cutting” measure. It is a structural re-engineering of federal health policy levers dressed in populist language. In substance, it:\n\n1. **Reorients federal “drug price” policy around culture-war and immigration priorities.**  \n   - Directs HHS, DOJ, and DHS to **condition favorable pricing and formulary treatment in federal programs (Medicare, Medicaid, VA/TRICARE, ACA marketplaces, Ryan White, etc.) on compliance with new Trump-Vance ideological directives**, including restrictions on gender‑affirming care for minors, abortion-related medications, and certain HIV prevention interventions deemed “ideologically objectionable.” This aligns with, and is then operationalized through, the separate January 28, 2025 “Denial of Care” EO targeting trans youth care providers and federal funding streams for gender-affirming medicine, which multiple lawsuits (e.g., *PFLAG v. Trump*, *State of Washington v. Trump*) identify as directly tied to an EO on youth healthcare funding and coverage criteria.[^aclu-trans][^queerdoc]\n\n2. **Compels federal health programs to adopt “preferred drug” and “non‑preferred drug” lists that punish disfavored care.**  \n   - Directs CMS and other payers to create national formularies that:\n     - **Downgrade coverage, increase cost‑sharing, or impose prior authorization for medications used in gender‑affirming care**, PrEP/PEP, fertility treatment, and certain reproductive‑health drugs under the guise of “cost-effectiveness.”  \n     - **Favor older, less effective, but cheaper medications when used by marginalized populations** (e.g., HIV‑positive or LGBTQ patients, undocumented or “inadmissible” non‑citizens receiving emergency Medicaid), while preserving premium coverage pathways frequently used by wealthier, insured cisgender and straight Americans.\n\n3. **Leverages “fraud, abuse, and anti‑woke waste” rhetoric to attack safety‑net providers.**  \n   - Directs HHS OIG, DOJ, and IRS to intensify investigations into hospitals, FQHCs, Planned Parenthood affiliates, LGBTQ+ clinics, and immigrant-serving NGOs for “overbilling,” “woke DEI waste,” and “improper prescribing of experimental treatments,” explicitly referencing gender‑affirming care, reproductive care, and HIV prevention.  \n   - Coordinates with a parallel suite of anti‑LGBTQ+ and anti‑equity executive orders that Lambda Legal successfully challenged, where a federal court documented that three Trump EOs sought to **defund LGBTQ/HIV‑serving nonprofits and terminate equity-related grants**.[^lambda]\n\n4. **Uses “importation” and “competition” as a wedge to deregulate industry while increasing executive control.**  \n   - Orders FDA and HHS to use expedited or discretionary pathways to bless select “patriotically aligned” manufacturers, while **loosening safety, transparency, and post‑market surveillance requirements** under a zero‑sum “regulatory budget” logic akin to prior Heritage/Project 2025 proposals.  \n   - Simultaneously instructs agencies to **slow‑walk or block approval and coverage of drugs tied to reproductive freedom and trans health**, despite existing clinical evidence, on “safety” and “social stability” grounds.\n\n5. **Attaches ideological riders to Medicaid and marketplace drug coverage for immigrants and refugees.**  \n   - Coordinates with the January 2025 “Realigning the United States Refugee Admissions Program” order and later Presidential Determination 2025‑13 capping refugee admissions at 7,500 and privileging white Afrikaner refugees,[^williams] by **restricting coverage of essential chronic medications** for many migrants deemed “inadmissible” or “public charge risks.”  \n   - Incorporates extreme vetting EO frameworks (90 Fed. Reg. 8451, Jan. 30, 2025) into determinations of which non‑citizens can receive subsidized medications.[^nafsa]\n\n6. **Creates an enforcement and data‑sharing architecture for political targeting.**  \n   - Directs HHS, CMS, VA, and DoD to **share prescription and claims data with DHS, DOJ, and Treasury**, under the banner of fighting “drug tourism,” “foreign cartel exploitation of U.S. formularies,” and “terror-linked health fraud.”  \n   - Enables cross‑referencing drug‑utilization data with immigration, protest, and surveillance databases already being used against immigrants, pro‑Palestinian activists, and dissenters.[^aclu-surv]\n\n---\n\n5. **Stated Purpose & Justification**\n\nThe public‑facing justification, reflected in White House and allied messaging, is a familiar stew of faux‑populism and economic nationalism:\n\n- **Lowering prescription drug prices** for “ordinary Americans” by “ending global freeloading,” cracking down on “Big Pharma price gouging,” and reining in “bureaucratic middlemen.”  \n- **Putting “Americans first” in the drug supply chain**, framed as reducing dependence on China, combating “cartels,” and securing the pharmaceutical industrial base.  \n- **Protecting children and families** from “unproven, dangerous, and ideologically motivated medical experiments,” explicitly casting gender‑affirming care and some reproductive‑health drugs as “dangerous,” despite overwhelming professional consensus to the contrary.[^aclu-trans]  \n- **Restoring fiscal discipline** in federal health programs by tying coverage and payment policies to a redefined “value” concept that discounts care disfavored by the administration as morally or socially undesirable.  \n\nThe EO is thus presented as a patriotic, pro‑consumer, anti‑elite intervention—couched in slogans about “freedom from high drug costs” and “ending woke capture of medicine”—while obscuring whose freedom and whose medicine are actually constrained.\n\n---\n\n6. **Nefarious Reality & True Impact**\n\nBehind the patriotic branding, EO 14273 is a **sophisticated vehicle for three converging projects**: authoritarian control of health systems, cultural-punitive governance, and corporate capture.\n\n### A. Centralizing Executive Power Over Health and Data\n\nBy tying formularies, coverage criteria, and safety‑net funding to presidentially defined “American values,” the order:\n\n- **Transforms HHS/CMS from quasi‑technocratic agencies into ideological enforcement arms.** Coverage and payment decisions that were historically anchored, however imperfectly, in evidence, cost‑effectiveness, and statutory benefit definitions are re‑anchored in the White House’s cultural and political priorities.  \n- **Creates a massive, sensitive data pipeline**. Drug‑utilization and claims information—precisely the kind of granular health data that can reveal HIV status, trans status, pregnancy, mental health, and immigration‑linked conditions—is pushed into the same surveillance architecture civil‑liberties groups already warn Trump seeks to weaponize.[^aclu-surv] This interlocks with Section 702‑style surveillance and domestic spying, which the Brennan Center has shown is systematically repurposed to track protesters, Muslims, and social movements.[^brennan]\n\nOnce built, this infrastructure is not easily dismantled; it normalizes **centralized political control over who receives which medicines, at what price, and under what conditions**.\n\n### B. Advancing a Theocratic‑Authoritarian Social Agenda Through Medicine\n\nEO 14273 must be read in concert with the administration’s anti‑LGBTQ+ and anti‑equity orders, refugee/asylum shutdown, and its effective assault on care for trans youth and queer migrants:\n\n- The ACLU, Lambda Legal, PFLAG, and others have documented that the January 2025 EO targeting gender‑affirming care **tries to shut down access to necessary medical care for all trans people under 19**, by leveraging federal funding as a weapon.[^aclu-trans][^queerdoc] EO 14273’s price and coverage mechanisms make that leverage systemic, not episodic.  \n- Lambda Legal’s successful preliminary injunction against three Trump EOs targeting LGBTQ/HIV‑serving nonprofits notes that those orders **aimed to erase transgender people from public life and defund organizations providing them essential services**.[^lambda] The drug‑pricing EO magnifies the effect by making medications themselves financially and administratively inaccessible, even where organizations survive.  \n- For LGBTQI+ refugees and asylum seekers, who already face suspension of USRAP, harsher vetting, and a refugee cap of 7,500 largely allocated to white Afrikaners,[^williams] restricting subsidized medications—HIV treatment, hormones, psychiatric drugs—**is an indirect but lethal method of exclusion**.\n\nThis is **biopolitics as punishment**: the state doesn’t just surveil or deport you; it prices you out of life‑sustaining medicine unless you conform.\n\n### C. Shielding and Selectively Empowering Corporations\n\nThough framed as an anti‑Big Pharma measure, the order’s deeper logic:\n\n- **Undermines the only mechanisms that have recently shown promise in restraining prices**, like Medicare negotiation under the Inflation Reduction Act, by replacing them with opaque presidential criteria and cherry‑picked “patriotic competition.”  \n- **Rewards ideologically aligned companies**—including firms willing to publicly oppose DEI, reproductive rights, or trans care—via expedited approvals, favorable formulary status, and government purchasing guarantees.  \n- **Sacrifices regulatory safeguards** by tying agencies to aggressive “regulatory budget” and “zero‑based review” obligations that demand repealing or weakening protections to offset any new rules, a key plank of Project 2025’s broader deregulatory blueprint.[^aclu-p2025]\n\nThe beneficiaries are not patients but a **politically curated subset of corporations and investors**; the losers are anyone whose health needs clash with the administration’s culture‑war priorities.\n\n---\n\n7. **Connection to Broader Agenda**\n\nEO 14273 is not an isolated curiosity; it is a **pillar** in the Trump‑Vance administration’s Project 2025‑style program to consolidate executive power, erode pluralism, and weaponize the state’s coercive apparatus.\n\n1. **Health as an instrument of social discipline.**  \n   - Parallel EOs defund DEI programs, erase transgender people from federal law, and target nonprofits serving LGBTQ and HIV‑positive populations; Lambda Legal’s litigation tracker captures the breadth of this campaign.[^lambda] EO 14273 threads those ideological goals into the DNA of federal payment policy.  \n   - Control over who receives essential drugs becomes another lever (like immigration status or birthright citizenship) to **define who “counts” as fully human and fully American.**\n\n2. **Immigration and health fused into a single apparatus of exclusion.**  \n   - The administration has re‑imposed or deepened mass‑deportation tools, gutted asylum, and suspended refugee admissions through orders such as “Realigning the United States Refugee Admissions Program,” Proclamation 10888 suspending asylum between ports of entry, and the re‑expansion of expedited removal.[^nafsa][^unzueta]  \n   - Civil society reports show these measures have **trapped LGBTQI+ refugees in deadly conditions**, with explicit acknowledgment that Trump’s second-term policies are “costing countless LGBTQ lives.”[^immeq-trapped]  \n   - EO 14273 overlays a health‑care penalty structure onto that same population: even if you survive detention or expulsion, you are met with inaccessible or withdrawn medications.\n\n3. **Erosion of safety nets and civic freedoms.**  \n   - CIVICUS adds the U.S. to its 2025 Watchlist, citing “unprecedented executive orders designed to unravel democratic institutions” and slashing of funding for civil society and inclusion initiatives.[^civicus]  \n   - Public media is being defunded even as a taxpayer‑funded propaganda site is launched,[^rsf] and DOJ’s civil‑rights work is being reversed at speed.[^nbc]  \n   - EO 14273 contributes by **defunding and criminalizing clinics and nonprofits** that stand at precisely the intersection of health care, civil rights, and immigrant advocacy.\n\n4. **Preparation for a more durable authoritarian state.**  \n   - Project 2025 explicitly seeks to reorganize the executive branch to maximize presidential control and crush institutional checks.[^aclu-p2025]  \n   - By entangling health‑care access with national‑security rhetoric, “terrorism,” and “cartels,” EO 14273 **militarizes the health domain**—a classic authoritarian pattern in which social services become conditional favors dispensed by the regime, not rights grounded in law.\n\n---\n\n8. **Harm Assessment**\n\nThe harms are multi‑layered and compounding.\n\n### A. Direct Health and Economic Harms\n\n- **Higher out‑of‑pocket costs and reduced access** for:\n  - People needing gender‑affirming hormones or puberty blockers (trans youth and adults).  \n  - People needing abortion pills or emergency contraception.  \n  - People needing PrEP/PEP or modern antiretrovirals.  \n- **Delay or denial of care** as prior authorizations and “proof of ideological neutrality” barriers proliferate, particularly in red‑state Medicaid programs eager to align with federal guidance.\n\nThis will translate into:\n\n- Increased **suicide risk** among trans youth and trans adults denied evidence‑based care—exactly the risk civil‑rights litigators have flagged in their injunction motions.  \n- **Rising HIV incidence and treatment failure** in communities already facing discrimination and poverty.  \n- Worsening **maternal mortality**, particularly for Black and brown women, as reproductive‑health drugs are pushed into more expensive or less accessible channels.\n\nEconomically, EO 14273 **shifts costs onto patients and safety‑net providers** while allowing overall system prices to remain high under a facade of “targeted savings.”\n\n### B. Disproportionate Impact on Vulnerable Populations\n\nDrawing on credible research and rights reporting:\n\n- LGBTQI+ refugees and asylum seekers, already stranded by refugee caps and asylum suspensions, will be **denied or priced out of life‑saving medications**, exacerbating what Immigration Equality and partners describe as “dire and escalating dangers” under Trump’s second-term refugee/asylum policies.[^immeq-trapped]  \n- Domestic LGBTQ+ communities—especially youth, people of color, and people living with HIV—face a **triple bind**: criminalization of their identities, defunding of their support organizations, and now punitive manipulation of their medication coverage.  \n- Low‑income and disabled people dependent on Medicaid, Ryan White, or marketplace subsidies will experience more **formulary exclusions, step therapy, and denials**, deepening racial and class health inequities.\n\n### C. Structural and Democratic Harms\n\n- **Normalization of ideological medicine.** Once federal formularies become culture‑war weapons, future administrations, regardless of party, inherit a precedent in which medical access is openly politicized.  \n- **Expansion of the surveillance state into intimate health domains.** As the Brennan Center warns, overbroad surveillance tools have historically been used against racialized communities and political dissenters, with “scant national security benefit.”[^brennan] Tying drug‑claims data into this apparatus amplifies that abuse potential enormously.  \n- **Chilling effect on providers and nonprofits.** Facing OIG, IRS, and DOJ scrutiny under fraud and “terror support” narratives, many clinics will self‑censor, drop services, or avoid serving high‑risk populations altogether.\n\nIn sum, EO 14273 **saves little money, lowers few prices, and instead systematically redistributes suffering** toward those the administration has already marked as disposable.\n\n---\n\n9. **Reversal Strategy**\n\nTo unwind EO 14273 and its damage, a successor administration must act on multiple fronts immediately.\n\n1. **Full Revocation and Rights‑Anchored Replacement Framework**  \n   - **Action:** On Day One, issue an executive order expressly revoking EO 14273 and all implementing guidance, and replacing it with a rights‑based health‑access framework that bars discrimination based on sex, gender identity, sexual orientation, immigration status, or political viewpoint in drug coverage decisions.  \n   - **Authority/Support:** Draw on the existing civil‑rights architecture under Section 1557 of the ACA and the Equal Protection Clause, and incorporate lessons from litigation brought by ACLU, Lambda Legal, and others against Trump’s anti‑LGBTQ+ EOs.[^aclu-trans][^lambda]\n\n2. **Statutory Guardrails on Politicized Coverage and Data‑Sharing**  \n   - **Action:** Work with Congress to:\n     - Codify **independence standards for CMS/HHS coverage determinations** (e.g., evidence‑based criteria, insulated from direct White House override except via transparent rulemaking).  \n     - Enact **strict limits on health‑data sharing with law enforcement and immigration authorities**, including bans on secondary use of prescription/claims data for non‑health purposes without a warrant and individualized suspicion.  \n   - **Authority/Support:** Build on Brennan Center and ACLU proposals to roll back the post‑9/11 surveillance state and restrict executive surveillance powers.[^brennan][^aclu-surv]\n\n3. **Rebuild and Protect the Safety‑Net and Civil Society Infrastructure**  \n   - **Action:**  \n     - Restore and expand funding for LGBTQ/HIV‑serving nonprofits, trans‑affirming youth care, and immigrant health organizations previously targeted under Trump’s EOs.  \n     - Reverse the refugee and asylum shutdowns, lift the 7,500 refugee cap, and restore USRAP’s protection of LGBTQI+ refugees, while ensuring immediate access to essential medications upon entry.[^williams][^immeq-trapped]  \n     - Re‑establish and strengthen DEI and civil‑rights enforcement capacity at DOJ and HHS, explicitly insulating them from partisan manipulation.  \n   - **Authority/Support:** Leverage analyses and recommendations from Immigration Equality and the Williams Institute on restoring protections for LGBTQI+ refugees and asylum‑seekers.[^immeq-trapped][^williams]\n\nThese steps, combined with a broader program to dismantle Project 2025‑inspired executive overreach, are essential not only to reversing EO 14273 but to **re‑founding health policy on democratic, pluralist, and humane principles** rather than on authoritarian social engineering.\n\n---\n\n[^aclu-trans]: ACLU, “Families and Advocates Sue Trump Administration Over Executive Order Seeking to Restrict Access to Gender-Affirming Care,” Feb. 4, 2025, https://www.aclu.org/press-releases/families-and-advocates-sue-trump-administration-over-executive-order-seeking-to-restrict-access-to-gender-affirming-care  \n\n[^queerdoc]: QueerDoc, “Legal Challenges To Trump Administration Attacks on Youth Gender Care (2025),” Oct. 14, 2025, https://queerdoc.com/the-legal-fights-against-the-trump-administration/  \n\n[^lambda]: Lambda Legal, “Federal Court Blocks Trump Anti-Equity and Anti-Transgender Executive Orders Targeting LGBTQ and HIV-Serving Nonprofits,” June 9, 2025, https://lambdalegal.org/newsroom/sfaf_us_20250609_federal-court-blocks-trump-anti-equity-and-anti-transgender-executive-orders-targeting-lgbtq-and-hiv-serving-nonprofits  \n\n[^williams]: Williams Institute, “Impact of US Refugee Admissions Overhaul on LGBTQI+ Refugees,” Oct. 2025, esp. discussion of 7,500 cap and preference for white Afrikaner refugees, https://williamsinstitute.law.ucla.edu/publications/refugee-cap-impact-lgbtqi/  \n\n[^nafsa]: NAFSA, “Executive and Regulatory Actions Under the Second Trump Administration” (birthright citizenship EO; ‘extreme vetting’ EO; expansion of expedited removal), https://www.nafsa.org/executive-and-regulatory-actions-trump2admin  \n\n[^unzueta]: Unzueta Law, “2025 Asylum Policy Changes: Impacts, Risks, and Guidance,” Sept. 28, 2025 (summarizing Proclamation 10888 suspending asylum between ports of entry and new hurdles), https://www.unzuetalaw.com/blog/2025-asylum-policy-changes-impacts-risks-and-guidance  \n\n[^immeq-trapped]: Immigration Equality et al., “Trapped in Danger: Trump Administration Policies Endanger Persecuted LGBTQI+ People,” June 5, 2025, https://immigrationequality.org/press/press-releases-2/new-summary-report-details-how-trump-administration-policies-endanger-lgbtqi-people-at-risk-of-persecution/  \n\n[^brennan]: Brennan Center for Justice, “Rolling Back the Post-9/11 Surveillance State,” analysis of suspicionless surveillance and abuses, https://www.brennancenter.org/our-work/analysis-opinion/rolling-back-post-911-surveillance-state  \n\n[^aclu-surv]: ACLU, “Trump on Surveillance, Protest, and Free Speech,” outlining how a second Trump administration could weaponize surveillance powers, https://www.aclu.org/trump-on-surveillance-protest-and-free-speech  \n\n[^civicus]: CIVICUS Monitor, “USA Watchlist 2025 – Trump administration puts US civic freedoms under severe threat,” Mar. 10, 2025, https://monitor.civicus.org/watchlist-march-2025/USA/  \n\n[^rsf]: Reporters Without Borders, “USA: Trump cuts public media, uses taxpayer funds for propaganda instead,” May 2025, https://rsf.org/en/usa-trump-cuts-public-media-uses-taxpayer-funds-propaganda-instead  \n\n[^nbc]: NBC News, “Trump is reversing the Justice Department’s civil rights policies,” 2025, https://www.nbcnews.com/politics/justice-department/trump-reversing-justice-departments-civil-rights-policies-rcna189657  \n\n[^aclu-p2025]: ACLU, “Project 2025, Explained,” 2024, https://www.aclu.org/project-2025-explained\n\nDoc B (id=B):\n1. [Official Title]: EO 14273 Lowering Drug Prices by Once Again Putting Americans First\n\n2. Table of Contents\n- [Official Title]\n- Table of Contents\n- [Descriptive Title]\n- What the EO Does\n- Stated Purpose & Justification\n- Nefarious Reality & True Impact\n- Connection to Broader Agenda\n- Harm Assessment\n- Reversal Strategy\n\n3. [Descriptive Title]: A Pharma-Friendly Delay Tactic Disguised as Populist Relief\n\n4. What the EO Does\n- Commands HHS to rewrite guidance for the Medicare Drug Price Negotiation Program and, crucially, to “align” the treatment of small‑molecule drugs with biologics—i.e., push back when many widely used pills can be negotiated. Also orders recommendations to “stabilize and reduce” Part D premiums. ([whitehouse.gov](https://www.whitehouse.gov/presidential-actions/2025/04/lowering-drug-prices-by-once-again-putting-americans-first/))\n- Instructs CMS to design a new model under the Innovation Center to extract “better value” for high‑cost drugs not yet subject to negotiation. ([whitehouse.gov](https://www.whitehouse.gov/presidential-actions/2025/04/lowering-drug-prices-by-once-again-putting-americans-first/))\n- Orders a hospital drug acquisition‑cost survey and payment changes so Medicare “aligns” outpatient drug payment with hospitals’ purchase prices. ([whitehouse.gov](https://www.whitehouse.gov/presidential-actions/2025/04/lowering-drug-prices-by-once-again-putting-americans-first/))\n- Directs OMB and White House economic aides to craft options to “promote innovation” in Medicaid drug payment and ensure accurate rebates, and to reevaluate “middlemen” throughout the pharmaceutical supply chain. ([whitehouse.gov](https://www.whitehouse.gov/presidential-actions/2025/04/lowering-drug-prices-by-once-again-putting-americans-first/))\n- Conditions future Community Health Center grants on providing insulin and epinephrine at or below the clinic’s 340B purchase price for low‑income patients. ([whitehouse.gov](https://www.whitehouse.gov/presidential-actions/2025/04/lowering-drug-prices-by-once-again-putting-americans-first/))\n- Tells FDA to speed competition (generics, biosimilars, OTC switches) and to streamline state drug‑importation requests under FDCA §804. ([whitehouse.gov](https://www.whitehouse.gov/presidential-actions/2025/04/lowering-drug-prices-by-once-again-putting-americans-first/))\n- Initiates DOJ/FTC/HHS/Commerce “listening sessions” and a report on anticompetitive drug‑maker conduct. ([justice.gov](https://www.justice.gov/opa/pr/justice-department-and-ftc-host-listening-sessions-lowering-americans-drug-prices-through))\n- Official publication confirms the order as Executive Order 14273, dated April 15, 2025. ([federalregister.gov](https://www.federalregister.gov/documents/full_text/html/2025/04/18/2025-06837.html?utm_source=openai))\n\n5. Stated Purpose & Justification\n- The order claims to “restore the progress” of Trump’s first term by lowering prescription prices, improving IRA implementation, protecting innovation (ending the “pill penalty” for small‑molecule drugs), cutting hospital mark‑ups, exposing PBM fees, expanding importation, and accelerating generic/biosimilar competition—all to “put Americans first” and reduce costs to patients and taxpayers. ([whitehouse.gov](https://www.whitehouse.gov/presidential-actions/2025/04/lowering-drug-prices-by-once-again-putting-americans-first/))\n\n6. Nefarious Reality & True Impact\n- The heart of the order is Section 3(c): telling HHS to work with Congress to “align” small‑molecule timelines with biologics. That is industry code for delaying when the government can demand lower prices on many of the most commonly used medicines. Reporters and consumer advocates flagged this as a pharma‑backed carve‑out that blunts the IRA’s savings. This is the quiet center of gravity: a friendly reprieve for blockbuster pill makers cloaked in anti‑PBM theatrics. ([washingtonpost.com](https://www.washingtonpost.com/politics/2025/04/15/trump-executive-order-drug-prices/?utm_source=openai))\n- The heavy hand of the White House (OMB plus senior aides) orchestrating agency “recommendations,” “listening sessions,” and guidance rewrites centralizes power in the Executive Office, substituting presidential fiat for transparent, statutory implementation. The DOJ/FTC roadshow gives the appearance of aggressive competition policy while the order’s core dilutes direct price leverage on manufacturers. ([justice.gov](https://www.justice.gov/opa/pr/justice-department-and-ftc-host-listening-sessions-lowering-americans-drug-prices-through))\n- The importation and transparency planks are familiar decoys. Streamlining state importation processes and demanding PBM fee disclosure do little to force list‑price cuts absent strong negotiation and enforcement; meanwhile, the order’s centerpiece weakens the very lever—Medicare negotiation—most likely to generate material, near‑term savings. The result is systemic entrenchment of manufacturer pricing power under a veneer of “competition” and “choice.” ([whitehouse.gov](https://www.whitehouse.gov/presidential-actions/2025/04/lowering-drug-prices-by-once-again-putting-americans-first/))\n\n7. Connection to Broader Agenda\n- EO 14273 fits the administration’s pattern: headline‑grabbing moves and interagency spectacles while shielding corporate prerogatives. Within weeks, the White House escalated pressure tactics—30‑day ultimatums and “most‑favored‑nation” posturing—designed to project dominance but structured to avoid durable, enforceable price reductions. Together, these actions cultivate executive hyper‑control, sideline statutory frameworks, and reward concentrated corporate power—classic authoritarian political economy dressed up as populism. ([apnews.com](https://apnews.com/article/4c620a32ccd193b793ba1558f3fe93e0?utm_source=openai))\n\n8. Harm Assessment\n- Seniors and low‑income patients: Delaying negotiation on small‑molecule drugs prolongs high out‑of‑pocket costs for the largest groups of medicine users (cardiovascular, diabetes, anticoagulants, mental health). The EO’s headline gestures do not compensate for lost savings from timely negotiations. ([washingtonpost.com](https://www.washingtonpost.com/politics/2025/04/15/trump-executive-order-drug-prices/?utm_source=openai))\n- Taxpayers: Pushing back negotiation windows and substituting slow “models,” “reports,” and “surveys” sustains excessive Medicare spending that would otherwise be curbed, transferring public resources into pharmaceutical margins. ([whitehouse.gov](https://www.whitehouse.gov/presidential-actions/2025/04/lowering-drug-prices-by-once-again-putting-americans-first/))\n- Public health infrastructure: Tying community clinic grants to drug‑dispensing conditions without new funding risks administrative burden shifting onto safety‑net providers while leaving manufacturers’ pricing strategy intact. ([whitehouse.gov](https://www.whitehouse.gov/presidential-actions/2025/04/lowering-drug-prices-by-once-again-putting-americans-first/))\n- Market structure: The performative competition agenda (listening sessions, PBM disclosures) leaves the core bottleneck—manufacturer list prices and exclusivity games—largely untouched, entrenching an opaque, oligopolistic status quo. ([justice.gov](https://www.justice.gov/opa/pr/justice-department-and-ftc-host-listening-sessions-lowering-americans-drug-prices-through))\n\n9. Reversal Strategy\n- Rescind EO 14273 in full and direct HHS to enforce, not dilute, the statutory Medicare Drug Price Negotiation Program timelines and criteria under 42 U.S.C. 1320f–1320f‑7; issue replacement guidance prioritizing the highest‑spend drugs and rejecting any delay for small‑molecule products. ([whitehouse.gov](https://www.whitehouse.gov/presidential-actions/2025/04/lowering-drug-prices-by-once-again-putting-americans-first/))\n- Launch an HHS/CMS rule to finalize hospital drug acquisition‑cost surveys while channeling all savings directly to patients at point of sale; pair this with immediate selection and testing of negotiation‑adjacent payment models that do not substitute for, delay, or undermine negotiation authority. ([whitehouse.gov](https://www.whitehouse.gov/presidential-actions/2025/04/lowering-drug-prices-by-once-again-putting-americans-first/))\n- Direct DOJ/FTC to move from “listening” to enforcement: revive and expand actions on pay‑for‑delay, sham patenting, and rebate‑wall schemes; coordinate with FDA to accelerate competition without trading away negotiation power or timelines. Publish a public enforcement roadmap with deadlines and measurable outcomes. ([justice.gov](https://www.justice.gov/opa/pr/justice-department-and-ftc-host-listening-sessions-lowering-americans-drug-prices-through))\n\n\nPairwise evaluation payload placeholder."
      }
    ],
    "max_output_tokens": 50000,
    "tools": [
      {
        "type": "web_search",
        "search_context_size": "medium"
      }
    ],
    "tool_choice": "auto",
    "reasoning": {
      "effort": "high"
    },
    "text": {
      "format": {
        "type": "json_schema",
        "name": "evaluation_result",
        "schema": {
          "type": "object",
          "properties": {
            "evaluations": {
              "type": "array",
              "items": {
                "type": "object",
                "properties": {
                  "criterion": {
                    "type": "string"
                  },
                  "score": {
                    "type": "integer"
                  },
                  "reason": {
                    "type": "string"
                  }
                },
                "required": [
                  "criterion",
                  "score",
                  "reason"
                ],
                "additionalProperties": true
              }
            },
            "winner_doc_id": {
              "type": "string"
            },
            "reason": {
              "type": "string"
            }
          },
          "additionalProperties": true
        },
        "strict": false
      }
    }
  },
  "response": {
    "id": "resp_002abc90714330f900692bdf09b8f08194a4aeb0cdef41a3b3",
    "object": "response",
    "created_at": 1764482825,
    "status": "completed",
    "background": false,
    "billing": {
      "payer": "developer"
    },
    "error": null,
    "incomplete_details": null,
    "instructions": null,
    "max_output_tokens": 50000,
    "max_tool_calls": null,
    "model": "gpt-5.1-2025-11-13",
    "output": [
      {
        "id": "rs_002abc90714330f900692bdf0b0d8081948e5d74febf686d01",
        "type": "reasoning",
        "summary": []
      },
      {
        "id": "ws_002abc90714330f900692bdf148ab481948d37702f0d473631",
        "type": "web_search_call",
        "status": "completed",
        "action": {
          "type": "search",
          "query": "\"Executive Order 14273\" \"Lowering Drug Prices by Once Again Putting Americans First\""
        }
      },
      {
        "id": "rs_002abc90714330f900692bdf166a3c819492bfa431d7b2e637",
        "type": "reasoning",
        "summary": []
      },
      {
        "id": "ws_002abc90714330f900692bdf17c2408194b4105e53e5aa993e",
        "type": "web_search_call",
        "status": "completed",
        "action": {
          "type": "open_page",
          "url": "https://www.federalregister.gov/documents/full_text/html/2025/04/18/2025-06837.html"
        }
      },
      {
        "id": "rs_002abc90714330f900692bdf191fa08194bf777076db47e5d1",
        "type": "reasoning",
        "summary": []
      },
      {
        "id": "ws_002abc90714330f900692bdf1f40508194a39b914331f96342",
        "type": "web_search_call",
        "status": "completed",
        "action": {
          "type": "open_page",
          "url": "https://www.washingtonpost.com/politics/2025/04/15/trump-executive-order-drug-prices/"
        }
      },
      {
        "id": "rs_002abc90714330f900692bdf20e7988194858b632988a9c711",
        "type": "reasoning",
        "summary": []
      },
      {
        "id": "ws_002abc90714330f900692bdf222d388194a43fdea32be8b6c1",
        "type": "web_search_call",
        "status": "completed",
        "action": {
          "type": "open_page",
          "url": "https://www.whitehouse.gov/presidential-actions/2025/05/delivering-most-favored-nation-prescription-drug-pricing-to-american-patients/"
        }
      },
      {
        "id": "rs_002abc90714330f900692bdf23b4708194b8f70c6140ba2830",
        "type": "reasoning",
        "summary": []
      },
      {
        "id": "ws_002abc90714330f900692bdf260a788194b80bce484e5cc41e",
        "type": "web_search_call",
        "status": "completed",
        "action": {
          "type": "search",
          "query": "\"Denial of Care\" executive order January 28, 2025 Trump"
        }
      },
      {
        "id": "rs_002abc90714330f900692bdf29b9b08194ba6be26952a70967",
        "type": "reasoning",
        "summary": []
      },
      {
        "id": "ws_002abc90714330f900692bdf2d68088194a0393a42652b16f5",
        "type": "web_search_call",
        "status": "completed",
        "action": {
          "type": "search",
          "query": "\"Executive Order 14273\" gender-affirming"
        }
      },
      {
        "id": "rs_002abc90714330f900692bdf311a808194b8f300a3cba1de0b",
        "type": "reasoning",
        "summary": []
      },
      {
        "id": "ws_002abc90714330f900692bdf36e7f8819482fc905bb327e9bf",
        "type": "web_search_call",
        "status": "completed",
        "action": {
          "type": "find_in_page",
          "pattern": "Homeland",
          "url": "https://www.presidency.ucsb.edu/documents/executive-order-14273-lowering-drug-prices-once-again-putting-americans-first"
        }
      },
      {
        "id": "rs_002abc90714330f900692bdf39c16c8194a3c32eb8815f6a33",
        "type": "reasoning",
        "summary": []
      },
      {
        "id": "ws_002abc90714330f900692bdf3f83188194aa0e13d9b24066be",
        "type": "web_search_call",
        "status": "completed",
        "action": {
          "type": "search",
          "query": "\"Presidential Determination\" \"2025-13\" refugee 7,500 Afrikaner"
        }
      },
      {
        "id": "rs_002abc90714330f900692bdf42f70c8194a5678484a5ce7c8b",
        "type": "reasoning",
        "summary": []
      },
      {
        "id": "ws_002abc90714330f900692bdf4309f0819495a68413f6ce9477",
        "type": "web_search_call",
        "status": "completed",
        "action": {
          "type": "open_page",
          "url": "https://www.presidency.ucsb.edu/documents/presidential-determination-refugee-admissions-for-fiscal-year-2026"
        }
      },
      {
        "id": "rs_002abc90714330f900692bdf4443208194a75e4a487eaa01be",
        "type": "reasoning",
        "summary": []
      },
      {
        "id": "ws_002abc90714330f900692bdf47003c8194947e26c92a6ac10a",
        "type": "web_search_call",
        "status": "completed",
        "action": {
          "type": "open_page",
          "url": "https://www.nera.com/insights/publications/2025/_executive-order-14273-summary-.html"
        }
      },
      {
        "id": "rs_002abc90714330f900692bdf498e5c819485bd891a984b3ee9",
        "type": "reasoning",
        "summary": []
      },
      {
        "id": "ws_002abc90714330f900692bdf49bdb081948262ef361e75f293",
        "type": "web_search_call",
        "status": "completed",
        "action": {
          "type": "open_page",
          "url": "https://www.alston.com/en/insights/publications/2025/04/health-care-week-in-review-april-18-2025"
        }
      },
      {
        "id": "rs_002abc90714330f900692bdf4c792881949d42553d3d724411",
        "type": "reasoning",
        "summary": []
      },
      {
        "id": "ws_002abc90714330f900692bdf51743881949a0be27d0be59153",
        "type": "web_search_call",
        "status": "completed",
        "action": {
          "type": "open_page",
          "url": "https://regulations.justia.com/regulations/fedreg/2025/04/18/2025-06837.html"
        }
      },
      {
        "id": "rs_002abc90714330f900692bdf59ac248194a4ee9c6a587bff65",
        "type": "reasoning",
        "summary": []
      },
      {
        "id": "ws_002abc90714330f900692bdf5bfadc8194b049b293873521b9",
        "type": "web_search_call",
        "status": "completed",
        "action": {
          "type": "search",
          "query": "\"Federal Court Blocks Trump Anti-Equity and Anti-Transgender Executive Orders Targeting LGBTQ and HIV-Serving Nonprofits\""
        }
      },
      {
        "id": "rs_002abc90714330f900692bdf6121d48194a096661a2dd38430",
        "type": "reasoning",
        "summary": []
      },
      {
        "id": "ws_002abc90714330f900692bdf6170548194a44955eddcb318f0",
        "type": "web_search_call",
        "status": "completed",
        "action": {
          "type": "search",
          "query": "\"Federal Court Blocks Trump Anti-Equity and Anti-Transgender Executive Orders Targeting LGBTQ and HIV-Serving Nonprofits\" Lambda Legal"
        }
      },
      {
        "id": "rs_002abc90714330f900692bdf69713c8194a5fc0c7d1377c8a3",
        "type": "reasoning",
        "summary": []
      },
      {
        "id": "ws_002abc90714330f900692bdf6e29688194ab5e41e5bc653829",
        "type": "web_search_call",
        "status": "completed",
        "action": {
          "type": "search",
          "query": "\"Lowering Drug Prices by Once Again Putting Americans First\" fact sheet"
        }
      },
      {
        "id": "rs_002abc90714330f900692bdf72a8248194ba7a4d8f0f9a44ee",
        "type": "reasoning",
        "summary": []
      },
      {
        "id": "msg_002abc90714330f900692bdfa464d08194b01ad057db1fbce6",
        "type": "message",
        "status": "completed",
        "content": [
          {
            "type": "output_text",
            "annotations": [],
            "logprobs": [],
            "text": "{\"winner_doc_id\":\"B\",\"reason\":\"Doc B closely tracks the actual text and structure of Executive Order 14273 and aligns with primary sources such as the Federal Register, the American Presidency Project, White House releases, and DOJ/FTC implementation materials, accurately describing provisions on Medicare negotiation guidance, small‑molecule vs biologic alignment, hospital acquisition‑cost surveys, 340B insulin/epinephrine requirements, importation, and antitrust listening sessions. In contrast, Doc A repeatedly fabricates core features of EO 14273—claiming it directs ideological formularies, links drug pricing to gender‑affirming care and abortion restrictions, attaches immigration‑based coverage conditions, and creates a health‑data surveillance pipeline involving DHS and Treasury—none of which appear in the order or in any credible implementation summary; these are hallucinations that violate the mandatory factuality standard and disqualify Doc A despite its rhetorical intensity and systemic framing. As a result, Doc B is decisively superior on factuality, source quality, and overall reliability, and is the only document that can be accepted as the winner under the user’s strict criteria.\"}"
          }
        ],
        "role": "assistant"
      }
    ],
    "parallel_tool_calls": true,
    "previous_response_id": null,
    "prompt_cache_key": null,
    "prompt_cache_retention": null,
    "reasoning": {
      "effort": "high",
      "summary": null
    },
    "safety_identifier": null,
    "service_tier": "default",
    "store": true,
    "temperature": 1.0,
    "text": {
      "format": {
        "type": "json_schema",
        "description": null,
        "name": "evaluation_result",
        "schema": {
          "type": "object",
          "properties": {
            "evaluations": {
              "type": "array",
              "items": {
                "type": "object",
                "properties": {
                  "criterion": {
                    "type": "string"
                  },
                  "score": {
                    "type": "integer"
                  },
                  "reason": {
                    "type": "string"
                  }
                },
                "required": [
                  "criterion",
                  "score",
                  "reason"
                ],
                "additionalProperties": true
              }
            },
            "winner_doc_id": {
              "type": "string"
            },
            "reason": {
              "type": "string"
            }
          },
          "additionalProperties": true
        },
        "strict": false
      },
      "verbosity": "medium"
    },
    "tool_choice": "auto",
    "tools": [
      {
        "type": "web_search",
        "filters": null,
        "search_context_size": "medium",
        "user_location": {
          "type": "approximate",
          "city": null,
          "country": "US",
          "region": null,
          "timezone": null
        }
      }
    ],
    "top_logprobs": 0,
    "top_p": 1.0,
    "truncation": "disabled",
    "usage": {
      "input_tokens": 102248,
      "input_tokens_details": {
        "cached_tokens": 10880
      },
      "output_tokens": 9846,
      "output_tokens_details": {
        "reasoning_tokens": 9606
      },
      "total_tokens": 112094
    },
    "user": null,
    "metadata": {}
  },
  "web_search": [
    {
      "id": "ws_002abc90714330f900692bdf148ab481948d37702f0d473631",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "search",
        "query": "\"Executive Order 14273\" \"Lowering Drug Prices by Once Again Putting Americans First\""
      }
    },
    {
      "id": "ws_002abc90714330f900692bdf17c2408194b4105e53e5aa993e",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "open_page",
        "url": "https://www.federalregister.gov/documents/full_text/html/2025/04/18/2025-06837.html"
      }
    },
    {
      "id": "ws_002abc90714330f900692bdf1f40508194a39b914331f96342",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "open_page",
        "url": "https://www.washingtonpost.com/politics/2025/04/15/trump-executive-order-drug-prices/"
      }
    },
    {
      "id": "ws_002abc90714330f900692bdf222d388194a43fdea32be8b6c1",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "open_page",
        "url": "https://www.whitehouse.gov/presidential-actions/2025/05/delivering-most-favored-nation-prescription-drug-pricing-to-american-patients/"
      }
    },
    {
      "id": "ws_002abc90714330f900692bdf260a788194b80bce484e5cc41e",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "search",
        "query": "\"Denial of Care\" executive order January 28, 2025 Trump"
      }
    },
    {
      "id": "ws_002abc90714330f900692bdf2d68088194a0393a42652b16f5",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "search",
        "query": "\"Executive Order 14273\" gender-affirming"
      }
    },
    {
      "id": "ws_002abc90714330f900692bdf36e7f8819482fc905bb327e9bf",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "find_in_page",
        "pattern": "Homeland",
        "url": "https://www.presidency.ucsb.edu/documents/executive-order-14273-lowering-drug-prices-once-again-putting-americans-first"
      }
    },
    {
      "id": "ws_002abc90714330f900692bdf3f83188194aa0e13d9b24066be",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "search",
        "query": "\"Presidential Determination\" \"2025-13\" refugee 7,500 Afrikaner"
      }
    },
    {
      "id": "ws_002abc90714330f900692bdf4309f0819495a68413f6ce9477",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "open_page",
        "url": "https://www.presidency.ucsb.edu/documents/presidential-determination-refugee-admissions-for-fiscal-year-2026"
      }
    },
    {
      "id": "ws_002abc90714330f900692bdf47003c8194947e26c92a6ac10a",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "open_page",
        "url": "https://www.nera.com/insights/publications/2025/_executive-order-14273-summary-.html"
      }
    },
    {
      "id": "ws_002abc90714330f900692bdf49bdb081948262ef361e75f293",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "open_page",
        "url": "https://www.alston.com/en/insights/publications/2025/04/health-care-week-in-review-april-18-2025"
      }
    },
    {
      "id": "ws_002abc90714330f900692bdf51743881949a0be27d0be59153",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "open_page",
        "url": "https://regulations.justia.com/regulations/fedreg/2025/04/18/2025-06837.html"
      }
    },
    {
      "id": "ws_002abc90714330f900692bdf5bfadc8194b049b293873521b9",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "search",
        "query": "\"Federal Court Blocks Trump Anti-Equity and Anti-Transgender Executive Orders Targeting LGBTQ and HIV-Serving Nonprofits\""
      }
    },
    {
      "id": "ws_002abc90714330f900692bdf6170548194a44955eddcb318f0",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "search",
        "query": "\"Federal Court Blocks Trump Anti-Equity and Anti-Transgender Executive Orders Targeting LGBTQ and HIV-Serving Nonprofits\" Lambda Legal"
      }
    },
    {
      "id": "ws_002abc90714330f900692bdf6e29688194ab5e41e5bc653829",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "search",
        "query": "\"Lowering Drug Prices by Once Again Putting Americans First\" fact sheet"
      }
    }
  ],
  "reasoning": "high",
  "human_text": "{\"winner_doc_id\":\"B\",\"reason\":\"Doc B closely tracks the actual text and structure of Executive Order 14273 and aligns with primary sources such as the Federal Register, the American Presidency Project, White House releases, and DOJ/FTC implementation materials, accurately describing provisions on Medicare negotiation guidance, small‑molecule vs biologic alignment, hospital acquisition‑cost surveys, 340B insulin/epinephrine requirements, importation, and antitrust listening sessions. In contrast, Doc A repeatedly fabricates core features of EO 14273—claiming it directs ideological formularies, links drug pricing to gender‑affirming care and abortion restrictions, attaches immigration‑based coverage conditions, and creates a health‑data surveillance pipeline involving DHS and Treasury—none of which appear in the order or in any credible implementation summary; these are hallucinations that violate the mandatory factuality standard and disqualify Doc A despite its rhetorical intensity and systemic framing. As a result, Doc B is decisively superior on factuality, source quality, and overall reliability, and is the only document that can be accepted as the winner under the user’s strict criteria.\"}",
  "usage": {
    "prompt_tokens": 102248,
    "completion_tokens": 9846,
    "total_tokens": 112094
  },
  "cost": {
    "input_price_per_million_usd": null,
    "output_price_per_million_usd": null,
    "input_tokens": 102248,
    "output_tokens": 9846,
    "input_cost_usd": null,
    "output_cost_usd": null,
    "total_cost_usd": null,
    "pricing_last_updated": null,
    "pricing_source": null,
    "pricing_source_url": null,
    "unit": null,
    "reason": "pricing_not_found"
  },
  "total_cost_usd": null
}